Ropivacaine, an aminoamide derivative, is used for local anesthetic agent as well as lidocaine, bupivacaine and mepivacaine ( Fig. 1) .
Liquid Chromatographic Determination of Plasma Ropivacaine for Assessing Pharmacokinetics of the Viscous Preparation
Preparation of Ropivacaine Viscous Ropivacaine viscous (0.5%) was prepared by using 1.88 g of carmellose sodium, 50 ml of ropivacaine (10 mg/ml), and a proper quantity of distilled water. The concentration of ropivacaine is 4 times lower than that of lidocaine viscous (2%), because the anesthetic activity of ropivacaine is known to be 4 times strong compared with lidocaine. 1, 2) The viscosity of the ropivacaine viscous measured by spindle type of rotational viscometer (KN3312482, TokyoKeiki, Tokyo, Japan), was 2150Ϯ50 centipoise (C.P.), which was somewhat higher degree of viscosity compared with lidocaine viscous (1850Ϯ50 C.P.). This value is suitable for viscous preparation in adhering the drug to oral mucosa.
HPLC Apparatus and Analytical Conditions HPLC system used for present study consisted of a pump (CCPD, TOSOH, Tokyo, Japan), an UV detector (UV-8010, TOSOH) and an integrator (C-R4A, Shimadzu, Kyoto, Japan). ODS column (TSK-GEL, 4.6 i.d.ϫ150 mm, TOSOH) as the analytical column was maintained at ambient temperature. The detection wavelength was set at 215 nm. The mobile phase solvent consisted of acetonitrile, methanol and 0.05 M phosphate buffer adjusted to pH 4.0 (10 : 30 : 60, v/v) was pumped at a flow rate of 0.8 ml/min.
Assay Procedures To 500 ml plasma sample in a 10 ml siliconized test tube, 100 ml IS solution (10 mg/ml) and 250 ml 0.1 M sodium hydroxide were added. After agitating the mixture, plasma sample was treated by 2 ml ethylacetate to extract ropivacaine and IS. The mixture was agitated for 1.5 min and was centrifuged at 1500 g for 6 min. The upper organic phase was transferred to another tube, and then the plasma sample was treated by further 2 ml ethylacetate. The upper organic phase was transferred to the tube again. The combined organic phase was evaporated to dryness under a stream of nitrogen at 40°C. The residue was dissolved in 100 ml of the mobile phase solvent and the 25 ml aliquot were injected into the HPLC column.
Application of Ropivacaine Viscous to Healthy Volunteers Two healthy male volunteers were enrolled for this study. The volunteers held 5 ml of 0.5% ropivacaine viscous in their mouths for 10 min and then, put out the drug from their mouths. Blood samples were collected before and 10, 20, 40, 60, 90, 120, 180 and 240 min after viscous administration. Informed consent was obtained from each subject, and the study was approved by The Ethical Committee of the University of Tsukuba.
Pharmacokinetic parameters (maximum drug concentration; C max , maximum drug concentration time; T max , area under the blood concentration time curve; AUC, half-life; t 1/2 and mean residence time; MRT) of ropivacaine was calculated by WinNonlin Standard (Pharsight Corporation, Mountain View, CA, U.S.A.).
RESULTS
Typical chromatograms for the blank plasma and the plasma spiked with ropivacaine and IS were shown in Fig. 2 . The peaks representing ropivacaine and IS were observed at the retention times of 8.4 and 13.8 min, respectively. Although there was minor interfering peak at the position of ropivacaine, the effects on routine determination of plasma ropivacaine was negligible. The detection limit of ropivacaine in plasma was as low as 25 ng/ml.
The calibration curve for determining plasma ropivacaine was linear at the concentration of 25-1000 ng/ml. The equation of the calibration curve calculated by regression analysis for ropivacaine was Yϭ1191.8XϪ28.946 (rϭ0.9998), where Y was the plasma ropivacaine concentration (ng/ml) and X, the peak height ratio of ropivacaine to IS.
The recoveries of ropivacaine from human plasma examined at concentrations of 25, 50, 250 and 1000 ng/ml were 87.9%, 93.3%, 98.8% and 96.7%, respectively, with the coefficient variation (CV) values less than 6.1% (Table 1 ). The assay precision of ropivacaine was evaluated by intra-and inter-day validation at the concentrations of 25, 50, 250 and 1000 ng/ml (Table 2 ). For intra-day assay precision, 5 sets of each control sample were assayed on the same day. For interday assay precision, 5 sets of each control sample were assayed on 5 different days. The CV values of the intra-and inter-day assay were 2.0-12.0% and 1.7-14.8%, respectively. The relative errors (bias) for intra-and inter-day assay were less than 2.4 and 8.0%, respectively.
The method was applied to determining the concentration-time profile for plasma ropivacaine in two healthy vol- unteers after applying ropivacaine viscous. The calculated pharmacokinetic parameters of ropivacaine, C max , T max , AUC, t 1/2 and MRT, were listed in Table 3 .
DISCUSSION
Our HPLC method using ethylacetate extraction and ODS column showed a sufficient selectivity and sensitivity for determination of plasma ropivacaine concentration. Solid phase extraction could not be used for pre-treatment of plasma because of the lower recovery rate (less than 80%) and several interfering peaks overlapping with ropivacaine. Our chromatographic conditions produced satisfactory separation of ropivacaine and IS from endogenous compounds (Fig. 2 ) without using column switching technique, which requires optional apparatus for the HPLC system. Also interfering peaks generated from concomitant drugs was not observed on the chromatogram of the plasma samples, which were obtained from patients receiving epidural anesthesia (data not shown). Assay precision of the present method, which was confirmed by the recovery and intra-and inter-day validations, was almost the same as the previous method. 12, 14, 17) The sensitivity was also sufficient to determine plasma ropivacaine in the subjects after receiving 0.5% ropivacaine viscous. It is considered that present method has an advantage in running cost compared with other methods in terms of the needless any items for sample pre-treatment such as cartridges and pre-column for column switching technique.
Our preliminary results suggest that 0.5% ropivacaine viscous can be used safely compared with commercially available 2.0% lidocaine viscous. This hypothesis is supported by previous report that the toxic range of plasma lidocaine concentration on central nervous system was 2152 ng/ml after administration of viscous preparation.
18) The C max of plasma ropivacaine observed in the present study was 89-125 ng/ml, which was ten times smaller than that of lidocaine. Moreover, the C max (89-125 ng/ml) is also lower than the plasma concentration of ropivacaine in previous reports that central nervous toxicity and adverse events of ropivacaine have been seen at the free plasma concentrations of 600 ng/ml 8) correspond to total plasma concentration of 1700 ng/ml. 19) Individual variation in pharmacokinetic parameters for ropivacaine was observed between two healthy subjects (Table 3) , though the blood concentrations were extremely low for assessing systemic activity of this drug. This may be due to difference in absorption of topical ropivacaine on oral mucosa and metabolic activity for systemic ropivacaine.
We need to confirm our preliminary data in healthy subjects with large number of population before assessing the efficacy of this new viscous preparation in clinical trial. 
